Loading…
Central Admixture Pharmacy Services, Inc., a registered outsourcing pharmacy, produced sterile drug products that failed to meet the conditions required under FDA regulations for compounding facility exemptions, resulting in a loss of sterility assurance. FDA investigators identified serious deficiencies in the facility's practices for producing sterile drugs during an inspection from July to August 2023, putting patients at risk and resulting in the company's de-registration in October 2023. The company initiated voluntary recalls of sterile drug products in July and September 2023 and subsequently decided to permanently cease operations at its San Diego location as of November 2023.